Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
55–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
New users of long-acting bronchodilators, Long-acting beta2-agonist (LABA) and long-acting muscarinic antagonists (LAMA) on the same date or of LABA, LAMA and inhaled corticosteroids (ICS), either as a fixed-dose combination (LABA-ICS) or free combination, on the same date between January 2002 and December 2016.
Diagnosis of Chronic obstructive pulmonary disease (COPD) prior to first maintenance inhaler and age ≥ 55 years at first maintenance inhaler.
You may not be if
Less than one year of medical history information prior to the date of combined treatment initiation (study cohort entry)
Asthma diagnosis prior to study cohort entry
Clareo Health | Effectiveness of Triple Therapy in COPD
